3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead

Eli Lilly, Merck and Gilead are due to report Q3 results on Oct. 29, with Lilly facing the sharpest estimate deterioration: its consensus EPS fell from $9.9319 to $6.6684 in 30 days, even as revenue is expected to rise 28.5% to $22.62B. Merck faces a roughly $250M prior-year wholesaler timing benefit that will not recur and slower Keytruda growth; Gilead’s risks include cash falling to $3.2B from $10.6B after acquisitions. The article highlights Lilly’s ability to offset 9% U.S. price declines through international growth and new launches as the key sector read-through.

Analysis

The key event risk is not the headline EPS beat/miss but whether management validates the revenue engine beneath charge-distorted per-share figures. For Eli Lilly, a lower EPS bar does not remove the harder test: incremental international volume must offset U.S. price pressure without weakening the full-year growth trajectory. The market may overreact to EPS noise; a guidance reduction or evidence that price cuts are outrunning volume would be more structurally important. Novo Nordisk is the clearest competitive read-through if Lilly signals weaker demand or pricing power, though one quarter would not establish a lasting share shift.

Merck’s risk is a slow-growth bridge: a tougher Keytruda comparison raises the importance of whether newer products can contribute enough to sustain revenue before the 2028 exclusivity transition. Moderna’s disappointing cancer-vaccine data could reduce perceived pipeline optionality for the partnership, but should not be treated as evidence of a near-term change in Merck’s core earnings. For Gilead, acquisition-related cash use is not by itself a solvency signal; the relevant follow-up is operating cash conversion, net debt and dividend coverage as launches scale.

Near term, expect event volatility and cross-sector read-through, especially from Lilly’s call. Over 1–3 months, revisions to guidance and launch trajectories matter more than reported EPS. Over 6–18 months, Lilly’s pricing/volume mix and Merck’s post-Keytruda replacement pipeline dominate. The contrarian risk is that investors anchor too heavily on Lilly’s EPS revisions and miss resilient demand—or, conversely, mistake rapid revenue growth for durable pricing power.

Key Decisions for Investors

• Avoid a pre-print directional LLY position; after results, consider a call spread only if international volume is accelerating and full-year revenue guidance is maintained. Invalidate the setup on a guidance cut or management evidence that U.S. price erosion is outpacing volume gains.
• Treat MRK as a pipeline-transition watch rather than a simple quarterly beat/miss trade. Reassess after the call using Keytruda growth excluding timing effects and contribution from Winrevair/QLEX; a weakening core trend without stronger newer-product momentum is the bearish signal.
• Keep GILD on a post-earnings watchlist, not an automatic short based on lower cash. Require improving launch contribution alongside stable cash conversion and dividend coverage before adding; verify cash flow, net debt and acquisition-related outlays in the filing.
• Use the three reports as a relative-demand check on pharma, but do not infer a durable LLY-to-Novo Nordisk share transfer from one quarter. A sustained change in volume, pricing commentary or guidance is needed to justify a longer-horizon relative-value position.